The US Food and Drug Administration (USFDA) had conducted inspection at the plant from March 24, 2025, to April 10, 2025, Aurobindo Pharma said in a regulatory filing.

Observations also suggest that this expansion reached a limit. Some recent field checks found signs of new seedlings taking hold in once-barren terrain. This could mean the local system is calming, at ...